This month a Genentech (Roche) drug known as Polatuzumab vedotin-piiq (Polivy) was approved by the Food and Drug Administration (FDA). The drug, a CD79b-directed antibody-drug conjugate (ADC) was approved for the treatment of diffuse large B-cell lymphoma (DLBCL) when...